# Tumor suppressor roles of TFEB in the development and maintenance of myeloid leukemia

> **NIH NIH K08** · H. LEE MOFFITT CANCER CTR & RES INST · 2021 · $238,752

## Abstract

PROJECT SUMMARY
This research proposal, prepared by Dr. Seongseok Yun, describes a five-year training program for the
development of an academic career in cancer research. Dr. Yun has several years of experience in molecular
pharmacology and cancer biology specifically focusing on hematologic neoplasms. Dr. Yun has recently begun
to study the role of TFEB in acute myeloid leukemia (AML) development and maintenance in Dr. Cleveland’s
laboratory. Dr. Yun identified that MYC represses TFEB and TFEB expression promotes myeloid differentiation
and cell death. Dr. Yun now proposes a detailed molecular and cell biological characterization of TFEB in MYC-
driven AML.
MYC oncoprotein is a transcriptional factor that coordinates the expression of genes involve in glycolysis,
glutaminolysis, and nutrient transport, thus promoting a shift to aerobic glycolysis. Although preclinical studies
have shown that MYC overexpression is sufficient to induce AML in mice, how MYC drives AML is not resolved.
Based upon preliminary observations that TFEB expression induces myeloid differentiation and cell death, Dr.
Yun proposes to characterize tumor suppressive role of TFEB in MYC-driven AML in vivo and in vitro. To this
end, Dr. Yun will utilize novel tools to study the effect of TFEB on AML suppression in Rosa26-LSL-MYC mouse
transplant model. Dr. Yun will assess whether MYC functions as a direct TFEB transcriptional repressor and
examine if TFEB expression impairs development and maintenance of MYC-driven AML in vivo. Also, he will
characterize the mechanisms of TFEB tumor suppression, specifically focusing on it roles in the epigenetic
modulation. These analyses will shed light on the tumor suppressive function of TFEB in AML and provide novel
therapeutic approaches.
Dr. Yun is committed to a career in biomedical research and has outlined a comprehensive Career Development
program to achieve his goal of independence. Dr. Cleveland’s laboratory will provide Dr. Yun with the opportunity
to gain additional expertise to become a well-rounded physician scientist. Dr. Yun will benefit from Moffitt and
USF’s stimulating environment that is created by close interactions with outstanding faculty and by multiple core
facilities that provide excellent research support. This program includes lectures and seminar series, scientific
conferences, and educational workshops and courses at Moffitt and USF. In addition, the guidance and advice
from Dr. Yun’s advisory committee and his collaborators - leaders in the field of hematological malignancies who
have proven track record of supporting the transition of their trainees to independence – will greatly facilitate his
transition to an independent investigator position.

## Key facts

- **NIH application ID:** 10232283
- **Project number:** 5K08CA237627-03
- **Recipient organization:** H. LEE MOFFITT CANCER CTR & RES INST
- **Principal Investigator:** Seongseok Yun
- **Activity code:** K08 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $238,752
- **Award type:** 5
- **Project period:** 2019-09-11 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10232283

## Citation

> US National Institutes of Health, RePORTER application 10232283, Tumor suppressor roles of TFEB in the development and maintenance of myeloid leukemia (5K08CA237627-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10232283. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*